Skip to main content

Workgroup Chairs:

Professor Michael O’Donovan and Professor James Walters

If you have questions concerning the projects this workgroup is undertaking, please contact the work group chair(s).

Outreach Liaison:

Dr Kimberley Kendall

If you have questions concerning this web page or our social media accounts, and/or you have resources that you would like to share with the public, please contact the work group outreach liaison(s).

Data Access Committee (DAC) Representative:

Vasa Tubetskoy

If you have any questions about accessing PGC SCZ data, please contact the DAC representative.

Schizophrenia Data Access Portal

About Us

The Schizophrenia workgroup has been part of the PCG since 2007. During that time, our membership has grown to include over 500 investigators from more than 100 institutions representing around 45 countries.

Our work focuses on establishing the genetic and pathophysiological basis of schizophrenia using approaches from genetics, bioinformatics and biostatistics; psychiatry, psychology and cognitive neuroscience; cellular modelling and drug discovery.

Our current goals are:

  • To expand our samples to include at least 150,000 people with schizophrenia, in order to capture more of the genetic variation that impacts on risk of the disorder,
  • To enhance the ancestral diversity of our samples in order to both capture more genetic variation and ensure the work benefits all human populations,
  • To use genomics to inform hypotheses of pathophysiological processes underlying schizophrenia,
  • To develop algorithms aimed at predicting important clinical outcomes e.g. treatment resistance,
  • To develop methods of stratifying individuals with schizophrenia, potentially with individuals with other psychiatric disorders, into subgroups that may be relatively homogeneous in order to identify patient strata who have different therapeutic needs,
  • To understand the relationships between schizophrenia, other psychiatric disorders, and physical co-morbidities,
  • To identify novel targets for therapeutics,
  • To identify risk and resilience exposures that might provide clues to prevention through the integration of genomics and epidemiology,
  • To impact on improved care through outreach with the public, patients, relatives and external academia and industry.

If you are interested in contributing to the workgroup, please contact Professors Michael O’Donovan and James Walters – in your e-mail please use the title ‘Membership of SCZ group of the PGC’. For existing members of the workgroup who wish to propose secondary analyses, please e-mail Vassily Trubetskoy. Further information can be found in the SCZ Data Access Portal (see above).


Lam M et al. 2019. Comparative genetic architectures of schizophrenia in East Asian and European populations. Nature Genetics 51, 1670 – 1678. PMID: 31740837.

Ripke S et al. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421 – 427. PMID: 25056061.

Cross-Disorder Group of the Psychiatric Genomics Consortium. 2019. Genomics relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell 179(7), 1469 – 1482. PMID: 31835028.


The Core activity of the group is funded by NIMH. Individual studies contributing to the PGC as well as secondary analyses are funded by hundreds of organizations across the world, governmental, charitable and industrial.